© 2021 MJH Life Sciences and Contagion Live. All rights reserved.
© 2021 MJH Life Sciences™ and Contagion Live. All rights reserved.
April 16, 2021
The company wants to transition to combination therapy of bamlanivimab and etesevimab together for COVID-19 treatment.
The ATLAS 2M study results showed non-inferiority in 2-month dosing compared to 1-month dosing for the cabotegravir and rilpivirine long-acting injectable.
Study finds a 10% reinfection rate amongst a mostly 18-20 year old United States Marine population in a closed setting.
April 15, 2021
Increased facility-level vaccine coverage amongst residents and staff was associated with lower cases in the latter population.